{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:24:02Z","timestamp":1794565442544,"version":"4.9.1"},"reference-count":28,"publisher":"Informa UK Limited","issue":"3","funder":[{"name":"Partnership for Safe Medicines"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Safety"],"published-print":{"date-parts":[[2026,3,4]]},"DOI":"10.1080\/14740338.2025.2499670","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T09:05:37Z","timestamp":1745658337000},"page":"581-588","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":30,"title":["Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system"],"prefix":"10.1080","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2061-108X","authenticated-orcid":false,"given":"Kenneth L.","family":"McCall","sequence":"first","affiliation":[{"name":"Binghamton University","place":["Johnson City, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keri A.","family":"Mastro Dwyer","sequence":"additional","affiliation":[{"name":"Binghamton University","place":["Johnson City, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan T.","family":"Casey","sequence":"additional","affiliation":[{"name":"Binghamton University","place":["Johnson City, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasnia N.","family":"Samana","sequence":"additional","affiliation":[{"name":"Binghamton University","place":["Johnson City, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa K.","family":"Sulicz","sequence":"additional","affiliation":[{"name":"Binghamton University","place":["Johnson City, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susannah Y.","family":"Tso","sequence":"additional","affiliation":[{"name":"Binghamton University","place":["Johnson City, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma R.","family":"Yalanzhi","sequence":"additional","affiliation":[{"name":"Binghamton University","place":["Johnson City, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Piper","sequence":"additional","affiliation":[{"name":"Geisinger Commonwealth School of Medicine","place":["Scranton, USA"]},{"name":"Center for Pharmacy Innovation and Outcomes, Geisinger","place":["Danville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"key":"e_1_3_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00203-5"},{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13543"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S009"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2023.02.001"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001168"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2022.06.008"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115032"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metop.2023.100236"},{"key":"e_1_3_7_10_1","unstructured":"FDA drug shortages [Internet]. [cited 2024 Nov 18]. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/drugshortages\/"},{"key":"e_1_3_7_11_1","unstructured":"KFF health tracking poll May 2024: the Public\u2019s use and views of GLP-1 drugs [Internet]. [cited 2024 Dec 19]. Available from: https:\/\/www.kff.org\/health-costs\/poll-finding\/kff-health-tracking-poll-may-2024-the-publics-use-and-views-of-glp-1-drugs\/"},{"issue":"5","key":"e_1_3_7_12_1","first-page":"367","article-title":"Pharmaceutical compounding: the oldest, most symbolic, and still vital part of pharmacy","volume":"20","author":"Kochanowska-Karamyan AJ.","year":"2016","unstructured":"Kochanowska-Karamyan AJ. Pharmaceutical compounding: the oldest, most symbolic, and still vital part of pharmacy. Int J Pharm Compd. 2016;20(5):367\u2013374.","journal-title":"Int J Pharm Compd"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/PTS.0000000000000188"},{"key":"e_1_3_7_14_1","unstructured":"Compounding and the FDA: questions and answers [internet]. FDA. 2024 [cited 2024 Nov 18]. Available from: https:\/\/www.fda.gov\/drugs\/human-drug-compounding\/compounding-and-fda-questions-and-answers"},{"key":"e_1_3_7_15_1","unstructured":"MedWatch forms for FDA safety reporting: instructions for completing form FDA 3500 [internet]. [cited 2025 Mar 18]. Available from: https:\/\/www.fda.gov\/safety\/medwatch-forms-fda-safety-reporting\/instructions-completing-form-fda-3500#B2"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.2337\/dci24-0091"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjad364"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph17020199"},{"key":"e_1_3_7_19_1","unstructured":"FDA alerts health care providers compounders and patients of dosing errors associated with compounded injectable semaglutide products [Internet]. [cited 2024 Oct 21]. Available from: https:\/\/www.fda.gov\/drugs\/human-drug-compounding\/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded"},{"key":"e_1_3_7_20_1","unstructured":"FDA\u2019s concerns with unapproved GLP-1 drugs used for weight loss [Internet]. [cited 2024 Nov 5]. Available from: https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"},{"key":"e_1_3_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2024.100127"},{"key":"e_1_3_7_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.2350"},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2295397"},{"key":"e_1_3_7_24_1","unstructured":"Update on FDA\u2019s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity [Internet]. [cited 2024 Nov 5]. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type"},{"key":"e_1_3_7_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-78345-y"},{"key":"e_1_3_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2021.10.005"},{"key":"e_1_3_7_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-016-0455-4"},{"key":"e_1_3_7_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.668"},{"key":"e_1_3_7_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1742"}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14740338.2025.2499670","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T15:57:35Z","timestamp":1772726255000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14740338.2025.2499670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,4]]}},"alternative-id":["10.1080\/14740338.2025.2499670"],"URL":"https:\/\/doi.org\/10.1080\/14740338.2025.2499670","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"value":"1474-0338","type":"print"},{"value":"1744-764X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,29]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-02-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}